資料載入中.....
|
請使用永久網址來引用或連結此文件:
https://ir.lib.ncu.edu.tw/handle/987654321/102800
|
| 題名: | MART-10, a new generation of vitamin d analog, is more potent than 1 α,25-dihydroxyvitamin Din inhibiting cell proliferation and inducing apoptosis in ER+ MCF-7 breast cancer cells |
| 作者: | 蘇立仁;Kittaka, Atsushi;Juang, Horng-Heng;Chen, Tai C.;Su, Li-Jen;Pang, Jong-Hwei S.;Yeh, Ta-sen;Hsu, Jun-Te;Shen, Shih-Che;Chen, Shin-Chih;Yeh, Chun-Nan;Chiang, Kun-Chun;Takano, Masashi |
| 貢獻者: | 生醫理工學院生醫科學與工程學系 |
| 關鍵詞: | Antitumor activity;Apoptosis;Biochemistry;Bone loss;Bone surgery;Breast cancer;Cancer therapies;Cell cycle;Cell growth;Cell proliferation;Cytochrome c;Cytosol;Deoxyribonucleic acid;DNA;Endocrinology;Estrogen receptors;Flow cytometry;G1 phase;Hypercalcemia;Immunoglobulins;Medical prognosis;Medical research;Metabolism;Mitochondria;Molecular biology;Morphology;Patients;Prostate cancer;Radiation therapy;Therapeutic applications;Vitamin D;Vitamin D3 |
| 日期: | 2012-12-01 |
| 上傳時間: | 2026-04-23 11:17:00 (UTC+8) |
| 出版者: | Hindawi Publishing Corporation;Cairo, Egypt: Hindawi Publishing Corporation |
| 摘要: | 摘要： Hormone antagonist therapy for estrogen receptor positive (ER+) breast cancer patients post radical surgery and radiation therapy has a poor prognosis and also causes bone loss. 1α,25-dihydroxyvitamin D3 [1α,25(OH)2D3] is a potent antitumor agent in pre-clinical studies, but caused hypercalcemia when its effective antitumor doses were used. Therefore, we investigated the effects of a less-calcemic 1α,25(OH)2D3 analog, 19-nor-2α-(3-hydroxypropyl)-1α,25-dihydroxyvitamin D3 (MART-10), on ER+MCF-7 cells. We demonstrate that MART-10 is 500- to 1000-fold more potent than 1α,25(OH)2D3 in inhibiting cell growth in a dose- and time-dependent manner. MART-10 is also much more potent in arresting MCF-7cell cycle progression at G0/G1 phase as compared to 1α,25(OH)2D3, possibly mediated by a greater induction of p21 and p27 expression. Moreover, MART-10 is more active than 1α,25(OH)2D3 in causing cell apoptosis, likely through a higher BAX/Bcl expression ratio and the subsequent cytochrome C release from mitochondria to cytosol. Based on our in vitro findings, MART-10 could be a promising vitamin D analog for the potential treatment of breast cancer, for example, ER+ patients, to decrease the tumor relapse rate and the side effect on bone caused by antihormone regimens. Thus, further in vivo animal study is warranted.
出版者： Cairo, Egypt: Hindawi Publishing Corporation
出版日期： 2012-01-01
出處： Evidence-based complementary and alternative medicine, 2012-01, Vol.2012 (2012), p.1-10
資源來源： ProQuest Open Access Content Collection
版權： Copyright © 2012 Kun-Chun Chiang et al.
版權： Copyright © 2012 Kun-Chun Chiang et al. This is an open access article distributed under the Creative Commons Attribution License (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. https://creativecommons.org/licenses/by/4.0
版權： Copyright © 2012 Kun-Chun Chiang et al. 2012
識別號： ISSN: 1741-427X
識別號： EISSN: 1741-4288
識別號： DOI: 10.1155/2012/310872
識別號： PMID: 23304196 |
| 顯示於類別: | [生醫科學與工程學系] 期刊論文
|
文件中的檔案:
| 檔案 |
描述 |
大小 | 格式 | 瀏覽次數 |
|---|
| index.html | | 0Kb | HTML | 11 | 檢視/開啟 |
|
在NCUIR中所有的資料項目都受到原著作權保護.
|
